Clinical Report: FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer

Overview

The FDA has approved daraxonrasib, an oral targeted therapy for metastatic pancreatic adenocarcinoma. This approval is based on the RASolute 302 Phase 3 trial.

Background

Pancreatic adenocarcinoma is the most prevalent form of pancreatic cancer, accounting for 90-95% of cases. Historically, treatment options have been limited, with chemotherapy providing minimal long-term success and significant side effects.

Data Highlights

Key Findings

• Daraxonrasib targets activated KRAS proteins, a key driver in pancreatic cancer.
• Median overall survival was 13.2 months for daraxonrasib compared to 6.7 months for chemotherapy.
• Patients on daraxonrasib had a 60% lower risk of death compared to those receiving standard chemotherapy.
• Progression-free survival was nearly double for patients on daraxonrasib.
• Daraxonrasib is the first significant advancement in treatment for advanced pancreatic cancer in many years.

Clinical Implications

The approval of daraxonrasib provides a new targeted treatment option for patients with metastatic pancreatic adenocarcinoma.

Conclusion

The introduction of daraxonrasib marks a new treatment option for metastatic pancreatic cancer.

Related Resources & Content

1. FDA, FDA, 2026 -- FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma
2. Baptist Health South Florida, Baptist Health South Florida, 2023 -- A New Era for Pancreatic Cancer: How Baptist Health Research Helped Get Us Here
3. ESMO Clinical Practice Guideline Express Update, Annals of Oncology, 2026 -- ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer
4. The ASCO Post — Tackling the Challenge of Pancreatic Cancer: New Approaches
5. The ASCO Post — Research Insights From the AACR Special Conference on Pancreatic Cancer
6. The ASCO Post — Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
7. Tackling the Challenge of Pancreatic Cancer: New Approaches
8. Research Insights From the AACR Special Conference on Pancreatic Cancer
9. Actionable mutations in pancreatic cancer: where targeted therapies are making a difference | BMJ Open Gastroenterology
10. FDA approves daraxonrasib for metastatic pancreatic adenocarcinoma | FDA
11. ESMO Clinical Practice Guideline Express Update on daraxonrasib in the treatment of metastatic pancreatic cancer - Annals of Oncology